CVS Health (NYSE:CVS) Issues FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 5.750-6.000 for the period, compared to the consensus EPS estimate of 5.970. The company issued revenue guidance of -.

CVS Health Price Performance

CVS stock traded up $2.16 during midday trading on Thursday, hitting $65.38. 2,507,002 shares of the stock were exchanged, compared to its average volume of 12,887,452. The stock’s 50-day moving average price is $50.71 and its 200-day moving average price is $55.94. The stock has a market cap of $82.27 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 0.60 and a beta of 0.61. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. Research analysts predict that CVS Health will post 5.14 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 4.07%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s payout ratio is currently 67.51%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CVS. Piper Sandler reduced their target price on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. Barclays boosted their price objective on CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday. Royal Bank of Canada reduced their price objective on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $69.89.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.